Characterizing the Influence of Preload Dosing on Percent Signal Recovery (PSR) and Cerebral Blood Volume (CBV) Measurements in a Patient Population with High-Grade Glioma Using Dynamic Susceptibility Contrast MRI

With DSC-MRI, contrast agent leakage effects in brain tumors can either be leveraged for percent signal recovery (PSR) measurements or be adequately resolved for accurate relative cerebral blood volume (rCBV) measurements. Leakage effects can be dimished by administration of a preload dose before im...

Full description

Saved in:
Bibliographic Details
Published inTomography (Ann Arbor) Vol. 3; no. 2; pp. 89 - 95
Main Authors Bell, Laura C., Hu, Leland S., Stokes, Ashley M., McGee, Samuel C., Baxter, Leslie C., Quarles, C. Chad
Format Journal Article
LanguageEnglish
Published United States Grapho Publications, LLC 01.06.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract With DSC-MRI, contrast agent leakage effects in brain tumors can either be leveraged for percent signal recovery (PSR) measurements or be adequately resolved for accurate relative cerebral blood volume (rCBV) measurements. Leakage effects can be dimished by administration of a preload dose before imaging and/or specific postprocessing steps. This study compares the consistency of both PSR and rCBV measurements as a function of varying preload doses in a retrospective analysis of 14 subjects with high-grade gliomas. The scans consisted of 6 DSC-MRI scans during 6 sequential bolus injections (0.05 mmol/kg). Mean PSR was calculated for tumor and normal-appearing white matter regions of interest. DSC-MRI data were corrected for leakage effects before computing mean tumor rCBV. Statistical differences were seen across varying preloads for tumor PSR (P value = 4.57E-24). Tumor rCBV values did not exhibit statistically significant differences across preloads (P value = .14) and were found to be highly consistent for clinically relevant preloads (intraclass correlation coefficient = 0.93). For a 0.05 mmol/kg injection bolus and pulse sequence parameters used, the highest PSR contrast between normal-appearing white matter and tumor occurs when no preload is used. This suggests that studies using PSR as a biomarker should acquire DSC-MRI data without preload. The finding that leakage-corrected rCBV values do not depend on the presence or dose of preload contradicts that of previous studies with dissimilar acquisition protocols. This further confirms the sensitivity of rCBV to preload dosing schemes and pulse sequence parameters and highlights the importance of standardization efforts for achieving multisite rCBV consistency.
AbstractList With DSC-MRI, contrast agent leakage effects in brain tumors can either be leveraged for percent signal recovery (PSR) measurements or be adequately resolved for accurate relative cerebral blood volume (rCBV) measurements. Leakage effects can be dimished by administration of a preload dose before imaging and/or specific postprocessing steps. This study compares the consistency of both PSR and rCBV measurements as a function of varying preload doses in a retrospective analysis of 14 subjects with high-grade gliomas. The scans consisted of 6 DSC-MRI scans during 6 sequential bolus injections (0.05 mmol/kg). Mean PSR was calculated for tumor and normal-appearing white matter regions of interest. DSC-MRI data were corrected for leakage effects before computing mean tumor rCBV. Statistical differences were seen across varying preloads for tumor PSR (P value = 4.57E-24). Tumor rCBV values did not exhibit statistically significant differences across preloads (P value = .14) and were found to be highly consistent for clinically relevant preloads (intraclass correlation coefficient = 0.93). For a 0.05 mmol/kg injection bolus and pulse sequence parameters used, the highest PSR contrast between normal-appearing white matter and tumor occurs when no preload is used. This suggests that studies using PSR as a biomarker should acquire DSC-MRI data without preload. The finding that leakage-corrected rCBV values do not depend on the presence or dose of preload contradicts that of previous studies with dissimilar acquisition protocols. This further confirms the sensitivity of rCBV to preload dosing schemes and pulse sequence parameters and highlights the importance of standardization efforts for achieving multisite rCBV consistency.With DSC-MRI, contrast agent leakage effects in brain tumors can either be leveraged for percent signal recovery (PSR) measurements or be adequately resolved for accurate relative cerebral blood volume (rCBV) measurements. Leakage effects can be dimished by administration of a preload dose before imaging and/or specific postprocessing steps. This study compares the consistency of both PSR and rCBV measurements as a function of varying preload doses in a retrospective analysis of 14 subjects with high-grade gliomas. The scans consisted of 6 DSC-MRI scans during 6 sequential bolus injections (0.05 mmol/kg). Mean PSR was calculated for tumor and normal-appearing white matter regions of interest. DSC-MRI data were corrected for leakage effects before computing mean tumor rCBV. Statistical differences were seen across varying preloads for tumor PSR (P value = 4.57E-24). Tumor rCBV values did not exhibit statistically significant differences across preloads (P value = .14) and were found to be highly consistent for clinically relevant preloads (intraclass correlation coefficient = 0.93). For a 0.05 mmol/kg injection bolus and pulse sequence parameters used, the highest PSR contrast between normal-appearing white matter and tumor occurs when no preload is used. This suggests that studies using PSR as a biomarker should acquire DSC-MRI data without preload. The finding that leakage-corrected rCBV values do not depend on the presence or dose of preload contradicts that of previous studies with dissimilar acquisition protocols. This further confirms the sensitivity of rCBV to preload dosing schemes and pulse sequence parameters and highlights the importance of standardization efforts for achieving multisite rCBV consistency.
With DSC-MRI, contrast agent leakage effects in brain tumors can either be leveraged for percent signal recovery (PSR) measurements or be adequately resolved for accurate relative cerebral blood volume (rCBV) measurements. Leakage effects can be dimished by administration of a preload dose before imaging and/or specific postprocessing steps. This study compares the consistency of both PSR and rCBV measurements as a function of varying preload doses in a retrospective analysis of 14 subjects with high-grade gliomas. The scans consisted of 6 DSC-MRI scans during 6 sequential bolus injections (0.05 mmol/kg). Mean PSR was calculated for tumor and normal-appearing white matter regions of interest. DSC-MRI data were corrected for leakage effects before computing mean tumor rCBV. Statistical differences were seen across varying preloads for tumor PSR (P value = 4.57E-24). Tumor rCBV values did not exhibit statistically significant differences across preloads (P value = .14) and were found to be highly consistent for clinically relevant preloads (intraclass correlation coefficient = 0.93). For a 0.05 mmol/kg injection bolus and pulse sequence parameters used, the highest PSR contrast between normal-appearing white matter and tumor occurs when no preload is used. This suggests that studies using PSR as a biomarker should acquire DSC-MRI data without preload. The finding that leakage-corrected rCBV values do not depend on the presence or dose of preload contradicts that of previous studies with dissimilar acquisition protocols. This further confirms the sensitivity of rCBV to preload dosing schemes and pulse sequence parameters and highlights the importance of standardization efforts for achieving multisite rCBV consistency.
With DSC-MRI, contrast agent leakage effects in brain tumors can either be leveraged for percent signal recovery (PSR) measurements or be adequately resolved for accurate relative cerebral blood volume (rCBV) measurements. Leakage effects can be dimished by administration of a preload dose before imaging and/or specific postprocessing steps. This study compares the consistency of both PSR and rCBV measurements as a function of varying preload doses in a retrospective analysis of 14 subjects with high-grade gliomas. The scans consisted of 6 DSC-MRI scans during 6 sequential bolus injections (0.05 mmol/kg). Mean PSR was calculated for tumor and normal-appearing white matter regions of interest. DSC-MRI data were corrected for leakage effects before computing mean tumor rCBV. Statistical differences were seen across varying preloads for tumor PSR ( P value = 4.57E-24). Tumor rCBV values did not exhibit statistically significant differences across preloads ( P value = .14) and were found to be highly consistent for clinically relevant preloads (intraclass correlation coefficient = 0.93). For a 0.05 mmol/kg injection bolus and pulse sequence parameters used, the highest PSR contrast between normal-appearing white matter and tumor occurs when no preload is used. This suggests that studies using PSR as a biomarker should acquire DSC-MRI data without preload. The finding that leakage-corrected rCBV values do not depend on the presence or dose of preload contradicts that of previous studies with dissimilar acquisition protocols. This further confirms the sensitivity of rCBV to preload dosing schemes and pulse sequence parameters and highlights the importance of standardization efforts for achieving multisite rCBV consistency.
With DSC-MRI, contrast agent leakage effects in brain tumors can either be leveraged for percent signal recovery (PSR) measurements or be adequately resolved for accurate relative cerebral blood volume (rCBV) measurements. Leakage effects can be dimished by administration of a preload dose before imaging and/or specific postprocessing steps. This study compares the consistency of both PSR and rCBV measurements as a function of varying preload doses in a retrospective analysis of 14 subjects with high-grade gliomas. The scans consisted of 6 DSC-MRI scans during 6 sequential bolus injections (0.05 mmol/kg). Mean PSR was calculated for tumor and normal-appearing white matter regions of interest. DSC-MRI data were corrected for leakage effects before computing mean tumor rCBV. Statistical differences were seen across varying preloads for tumor PSR ( value = 4.57E-24). Tumor rCBV values did not exhibit statistically significant differences across preloads ( value = .14) and were found to be highly consistent for clinically relevant preloads (intraclass correlation coefficient = 0.93). For a 0.05 mmol/kg injection bolus and pulse sequence parameters used, the highest PSR contrast between normal-appearing white matter and tumor occurs when no preload is used. This suggests that studies using PSR as a biomarker should acquire DSC-MRI data without preload. The finding that leakage-corrected rCBV values do not depend on the presence or dose of preload contradicts that of previous studies with dissimilar acquisition protocols. This further confirms the sensitivity of rCBV to preload dosing schemes and pulse sequence parameters and highlights the importance of standardization efforts for achieving multisite rCBV consistency.
Author Baxter, Leslie C.
Bell, Laura C.
Quarles, C. Chad
McGee, Samuel C.
Hu, Leland S.
Stokes, Ashley M.
Author_xml – sequence: 1
  givenname: Laura C.
  surname: Bell
  fullname: Bell, Laura C.
– sequence: 2
  givenname: Leland S.
  surname: Hu
  fullname: Hu, Leland S.
– sequence: 3
  givenname: Ashley M.
  surname: Stokes
  fullname: Stokes, Ashley M.
– sequence: 4
  givenname: Samuel C.
  surname: McGee
  fullname: McGee, Samuel C.
– sequence: 5
  givenname: Leslie C.
  surname: Baxter
  fullname: Baxter, Leslie C.
– sequence: 6
  givenname: C. Chad
  surname: Quarles
  fullname: Quarles, C. Chad
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28825039$$D View this record in MEDLINE/PubMed
BookMark eNp1UsFuEzEQXaEiWko_gAuaY3pI8K6z2fUFiW4hjdSKKKEVN8vrnU0cee1ge4vCf_I_OGmLChKWJY80b96bGb_XyZGxBpPkbUpGaUlL-n4zCrYbZSQtRiSe8YvkJKMFG6aUfTt6Fh8nZ95vIiIjWbzFq-Q4K8ssJ5SdJL-qtXBCBnTqpzIrCGuEmWl1j0Yi2BbmDrUVDVxav89bA3N0Ek2ApVoZoWGB0t6j28FgvlycgzANVOiwdjF3oa1t4M7qvkMYVBd353CDwvcOu8jgQRkQMBdB7fnmdtvrGEeJHyqs4Uqt1sOpEw3CVCvbCbg9tHC5M6JTEpa9l7gNqlZahR1U1gQnfICbxexN8rIV2uPZ43ua3H7-9LW6Gl5_mc6qj9dDSRkLwwyLXJRYEkLHbZHJ8SQlNc1zksqWTrCciIbSbMIIpqLM66Kts5qlgrW1pASZpKfJhwfebV932OzXEsfmW6c64XbcCsX_zhi15it7z_M8L0jOIsHgkcDZ7z36wDsVp9JaGLS95ymjhNF8QvIIffdc64_I019GQPEAkM5677DlUoXDPqO00jwl_GAcvuHROHxvHH4wTqxM_6l8Iv9_zW9iacqB
CitedBy_id crossref_primary_10_1007_s11060_019_03244_6
crossref_primary_10_1016_j_xcrm_2024_101464
crossref_primary_10_3389_fradi_2022_809373
crossref_primary_10_1007_s00234_020_02522_9
crossref_primary_10_1016_j_neurad_2018_04_006
crossref_primary_10_1038_s41467_023_41559_1
crossref_primary_10_1002_jmri_26837
crossref_primary_10_1016_j_artmed_2023_102607
crossref_primary_10_1016_j_neuroimage_2018_04_069
crossref_primary_10_1111_jon_13183
crossref_primary_10_1007_s00330_023_09917_1
crossref_primary_10_1177_0271678X211039597
crossref_primary_10_1007_s00330_023_09729_3
crossref_primary_10_3174_ajnr_A8099
ContentType Journal Article
Copyright 2017 The Authors. Published by Grapho Publications, LLC 2017 Grapho Publications, LLC
Copyright_xml – notice: 2017 The Authors. Published by Grapho Publications, LLC 2017 Grapho Publications, LLC
DBID AAYXX
CITATION
NPM
7X8
5PM
DOI 10.18383/j.tom.2017.00004
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef

PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2379-139X
EndPage 95
ExternalDocumentID PMC5557059
28825039
10_18383_j_tom_2017_00004
Genre Journal Article
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: R01 CA158079
GroupedDBID 53G
AAYXX
AFZYC
ALMA_UNASSIGNED_HOLDINGS
CITATION
GROUPED_DOAJ
HYE
MODMG
M~E
OK1
PGMZT
RPM
EMOBN
IAO
IGS
ITC
NPM
7X8
5PM
ID FETCH-LOGICAL-c399t-2e75a8e80034f72c4610b35501cf36e86ad332690e1a85b7fb2b91a9fbc30e9c3
ISSN 2379-139X
2379-1381
IngestDate Thu Aug 21 18:32:31 EDT 2025
Fri Jul 11 12:40:43 EDT 2025
Thu Jan 02 23:12:10 EST 2025
Thu Apr 24 23:01:41 EDT 2025
Tue Jul 01 01:51:00 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords percent signal recovery
DSC-MRI
preload doses
relative cerebral blood volume
Language English
License https://creativecommons.org/licenses/by/4.0
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c399t-2e75a8e80034f72c4610b35501cf36e86ad332690e1a85b7fb2b91a9fbc30e9c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://dx.doi.org/10.18383/j.tom.2017.00004
PMID 28825039
PQID 1930935605
PQPubID 23479
PageCount 7
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5557059
proquest_miscellaneous_1930935605
pubmed_primary_28825039
crossref_citationtrail_10_18383_j_tom_2017_00004
crossref_primary_10_18383_j_tom_2017_00004
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-06-01
2017-Jun
20170601
PublicationDateYYYYMMDD 2017-06-01
PublicationDate_xml – month: 06
  year: 2017
  text: 2017-06-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Ann Abor, Michigan
PublicationTitle Tomography (Ann Arbor)
PublicationTitleAlternate Tomography
PublicationYear 2017
Publisher Grapho Publications, LLC
Publisher_xml – name: Grapho Publications, LLC
References 15597757 - J Neurosurg. 2004 Dec;101(6):970-6
27505026 - Br J Radiol. 2016 Oct;89(1066):20160476
18780827 - Radiology. 2008 Nov;249(2):601-13
19585599 - Magn Reson Med. 2009 Sep;62(3):672-81
26362714 - Magn Reson Med. 2016 Aug;76(2):613-25
16421765 - Acta Neurochir (Wien). 2006 Mar;148(3):277-85; discussion 285
21505483 - J Cereb Blood Flow Metab. 2011 Oct;31(10 ):2041-53
19059349 - Neuroimage. 2009 Mar;45(1 Suppl):S173-86
23413249 - AJNR Am J Neuroradiol. 2013 Jul;34(7):1364-9
19749223 - AJNR Am J Neuroradiol. 2010 Jan;31(1):40-8
15502131 - AJNR Am J Neuroradiol. 2004 Oct;25(9):1524-32
28034995 - AJNR Am J Neuroradiol. 2017 Mar;38(3):478-484
26971534 - J Magn Reson Imaging. 2016 Nov;44(5):1229-1237
16611779 - AJNR Am J Neuroradiol. 2006 Apr;27(4):859-67
19789240 - Radiology. 2009 Nov;253(2):486-96
17659630 - Magn Reson Med. 2007 Jul;58(1):70-81
25227668 - Magn Reson Med. 2015 Sep;74(3):772-84
18372467 - Radiology. 2008 Apr;247(1):170-8
25907520 - AJNR Am J Neuroradiol. 2015 Jun;36(6):E41-51
19056837 - AJNR Am J Neuroradiol. 2009 Mar;30(3):552-8
25436828 - Am J Clin Oncol. 2017 Jun;40(3):228-234
26294301 - J Nucl Med. 2015 Oct;56(10 ):1554-61
22322605 - AJNR Am J Neuroradiol. 2012 Jun;33(6):1081-7
22281731 - J Magn Reson Imaging. 2012 Jun;35(6):1472-7
References_xml – reference: 19056837 - AJNR Am J Neuroradiol. 2009 Mar;30(3):552-8
– reference: 16611779 - AJNR Am J Neuroradiol. 2006 Apr;27(4):859-67
– reference: 25227668 - Magn Reson Med. 2015 Sep;74(3):772-84
– reference: 26362714 - Magn Reson Med. 2016 Aug;76(2):613-25
– reference: 19059349 - Neuroimage. 2009 Mar;45(1 Suppl):S173-86
– reference: 17659630 - Magn Reson Med. 2007 Jul;58(1):70-81
– reference: 21505483 - J Cereb Blood Flow Metab. 2011 Oct;31(10 ):2041-53
– reference: 23413249 - AJNR Am J Neuroradiol. 2013 Jul;34(7):1364-9
– reference: 28034995 - AJNR Am J Neuroradiol. 2017 Mar;38(3):478-484
– reference: 22281731 - J Magn Reson Imaging. 2012 Jun;35(6):1472-7
– reference: 18780827 - Radiology. 2008 Nov;249(2):601-13
– reference: 19585599 - Magn Reson Med. 2009 Sep;62(3):672-81
– reference: 15597757 - J Neurosurg. 2004 Dec;101(6):970-6
– reference: 26971534 - J Magn Reson Imaging. 2016 Nov;44(5):1229-1237
– reference: 25436828 - Am J Clin Oncol. 2017 Jun;40(3):228-234
– reference: 16421765 - Acta Neurochir (Wien). 2006 Mar;148(3):277-85; discussion 285
– reference: 15502131 - AJNR Am J Neuroradiol. 2004 Oct;25(9):1524-32
– reference: 22322605 - AJNR Am J Neuroradiol. 2012 Jun;33(6):1081-7
– reference: 25907520 - AJNR Am J Neuroradiol. 2015 Jun;36(6):E41-51
– reference: 26294301 - J Nucl Med. 2015 Oct;56(10 ):1554-61
– reference: 18372467 - Radiology. 2008 Apr;247(1):170-8
– reference: 27505026 - Br J Radiol. 2016 Oct;89(1066):20160476
– reference: 19789240 - Radiology. 2009 Nov;253(2):486-96
– reference: 19749223 - AJNR Am J Neuroradiol. 2010 Jan;31(1):40-8
SSID ssj0002022027
Score 2.0996468
Snippet With DSC-MRI, contrast agent leakage effects in brain tumors can either be leveraged for percent signal recovery (PSR) measurements or be adequately resolved...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 89
Title Characterizing the Influence of Preload Dosing on Percent Signal Recovery (PSR) and Cerebral Blood Volume (CBV) Measurements in a Patient Population with High-Grade Glioma Using Dynamic Susceptibility Contrast MRI
URI https://www.ncbi.nlm.nih.gov/pubmed/28825039
https://www.proquest.com/docview/1930935605
https://pubmed.ncbi.nlm.nih.gov/PMC5557059
Volume 3
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtNAEF2FIiFeEHfCTYPEQ4tlsNd2HD-m4dIiFUVNW_Ut2rU3JJDYVeI80P_kD_gQZnbXjpMCAl6iyN5sLM3x7Mzs2TOMvZQUdMSZ52ZSxm4os8BNeCdAg_hc8mwsQqlZvp86B6fhx_PovNX60WAtrUr5Or385bmS_7EqXkO70inZf7BsPSlewO9oX_xEC-PnX9m4X6stX1anng6rpiOa3LZQs0JkGCXrigAaekA8lrx0htPPuZbVT4nCqXf8B8NjKhFQIb2vFrSfPHP2idbunGkPpvd7989ozNG6sKjptIKU_ulgpTOo-4GhvyknmkbifliIjHgd02IuHMNRePstF8TKH66WmlejKbrknajWvCydo-PDZth8UsyttDY9RS_Pnd5CUqGhLmNU54zonLdYl34PVvqimmmGal1OKouvxj32lhPyis2Db7ZzgJiv1MxOZKsifrxmbxnnyYM4IX1Fv-npgwagecNrmyZGVxaTLmbvejUpC9Is8I3YZdgci3i4mGt0cUxVIs8IM20peFe3rrHrHJMZ3kj8v-itYE4VKN0F0T603X6nB3iz_fckX20n3IylriRI2zzfRuB0cpvdshkP9Ax877CWyu-yG0eW03GPfd9EMSCKoUYxFGOwKAaDYihysCgGg2KoUAy7iOE9QFNDhWDQCAaDYNhF_O5BE70wzUGARS-s0QuEXlijFwx6QaMXLHphE71QoRcQvffZ6ft3J_0D1zYbcVOM0UuXqzgSXdUlwaZxzFPqQyAxGPf8dBx0VLcjsgBTncRTvuhGMh5LLhNfJGOZBp5K0uAB28mLXD1igMukijiVfyQPkzBMaKGLUpnJSEjJVZt5ldlGqVXip4YwsxFl5GR0TMnR6CMy-kgbvc1e1T-5MDI0fxr8osLCCBcL2gEUuSpWyxFma0R86HhRmz002Kinq0DVZvEGauoBJES_eSefTrQgfUQ6flHy-LdzPmE31y_pU7ZTLlbqGQbzpXyu34WfR_D1Vw
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Characterizing+the+Influence+of+Preload+Dosing+on+Percent+Signal+Recovery+%28PSR%29+and+Cerebral+Blood+Volume+%28CBV%29+Measurements+in+a+Patient+Population+With+High-Grade+Glioma+Using+Dynamic+Susceptibility+Contrast+MRI&rft.jtitle=Tomography+%28Ann+Arbor%29&rft.au=Bell%2C+Laura+C&rft.au=Hu%2C+Leland+S&rft.au=Stokes%2C+Ashley+M&rft.au=McGee%2C+Samuel+C&rft.date=2017-06-01&rft.issn=2379-1381&rft.volume=3&rft.issue=2&rft.spage=89&rft_id=info:doi/10.18383%2Fj.tom.2017.00004&rft_id=info%3Apmid%2F28825039&rft.externalDocID=28825039
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2379-139X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2379-139X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2379-139X&client=summon